Patients with treatment-resistant depression weigh pros and cons of brain-implant devices

A new study surveyed individuals with treatment-resistant depression about their preferences and concerns regarding implantable brain devices aimed at alleviating mood symptoms.

Respondents highlighted factors such as surgical risk, device size, recovery time, and the clarity of how "minimally invasive" is defined. Many expressed uncertainty about what the phrase actually means.

Medical ethicist Anna Wexler from the University of Pennsylvania noted that the term is vague and can be used as marketing spin, making it hard for patients to compare technologies.

Companies including Synchron, Motif Neuroscience, Precision Neuroscience and Merge Labs frequently label their products as minimally invasive, a practice that journalists sometimes repeat without clarification.